These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 3021662)

  • 1. Synthesis and biodistribution of 18F-labeled fluoronitroimidazoles: potential in vivo markers of hypoxic tissue.
    Jerabek PA; Patrick TB; Kilbourn MR; Dischino DD; Welch MJ
    Int J Rad Appl Instrum A; 1986; 37(7):599-605. PubMed ID: 3021662
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis and evaluation of 4-bromo-1-(3-[18F]fluoropropyl)-2-nitroimidazole with a low energy LUMO orbital designed as brain hypoxia-targeting imaging agent.
    Yamamoto F; Aoki M; Furusawa Y; Ando K; Kuwabara Y; Masuda K; Sasaki S; Maeda M
    Biol Pharm Bull; 2002 May; 25(5):616-21. PubMed ID: 12033502
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and characterization of lipophilic 1-[18F]fluoroalkyl-2-nitroimidazoles for imaging hypoxia.
    Yamamoto F; Oka H; Antoku S; Ichiya Y; Masuda K; Maeda M
    Biol Pharm Bull; 1999 Jun; 22(6):590-7. PubMed ID: 10408232
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis and characterization of congeners of misonidazole for imaging hypoxia.
    Grunbaum Z; Freauff SJ; Krohn KA; Wilbur DS; Magee S; Rasey JS
    J Nucl Med; 1987 Jan; 28(1):68-75. PubMed ID: 3794812
    [TBL] [Abstract][Full Text] [Related]  

  • 5. No-carrier-added synthesis of 3-[18F]fluoro-1-(2-nitro-1-imidazolyl)-2-propanol. A potential PET agent for detecting hypoxic but viable tissues.
    Hwang DR; Dence CS; Bonasera TA; Welch MJ
    Int J Rad Appl Instrum A; 1989; 40(2):117-26. PubMed ID: 2541102
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An efficient radiosynthesis of [18F]fluoromisonidazole.
    Lim JL; Berridge MS
    Appl Radiat Isot; 1993 Aug; 44(8):1085-91. PubMed ID: 8358398
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Noninvasive assessment of tumor hypoxia with 99mTc labeled metronidazole.
    Yang DJ; Ilgan S; Higuchi T; Zareneyrizi F; Oh CS; Liu CW; Kim EE; Podoloff DA
    Pharm Res; 1999 May; 16(5):743-50. PubMed ID: 10350019
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Iodine-124-labeled iodo-azomycin-galactoside imaging of tumor hypoxia in mice with serial microPET scanning.
    Zanzonico P; O'Donoghue J; Chapman JD; Schneider R; Cai S; Larson S; Wen B; Chen Y; Finn R; Ruan S; Gerweck L; Humm J; Ling C
    Eur J Nucl Med Mol Imaging; 2004 Jan; 31(1):117-28. PubMed ID: 14523586
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A robotic synthesis of [18F]fluoromisonidazole ([18F]FMISO).
    Chang CW; Chou TK; Liu RS; Wang SJ; Lin WJ; Chen CH; Wang HE
    Appl Radiat Isot; 2007 Jun; 65(6):682-6. PubMed ID: 17379530
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Imaging of ischemic but viable myocardium using a new 18F-labeled 2-nitroimidazole analog, 18F-FRP170.
    Kaneta T; Takai Y; Kagaya Y; Yamane Y; Wada H; Yuki M; Iwata R; Tsujitani M; Takahashi S; Yamada S
    J Nucl Med; 2002 Jan; 43(1):109-16. PubMed ID: 11801713
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of radiolabeled fluoromisonidazole as a probe for hypoxic cells.
    Rasey JS; Grunbaum Z; Magee S; Nelson NJ; Olive PL; Durand RE; Krohn KA
    Radiat Res; 1987 Aug; 111(2):292-304. PubMed ID: 3628717
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the biodistribution of two hypoxia markers [18F]FETNIM and [18F]FMISO in an experimental mammary carcinoma.
    Grönroos T; Bentzen L; Marjamäki P; Murata R; Horsman MR; Keiding S; Eskola O; Haaparanta M; Minn H; Solin O
    Eur J Nucl Med Mol Imaging; 2004 Apr; 31(4):513-20. PubMed ID: 14722675
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of [18F]FETNIM: a potential marker for PET.
    Grönroos T; Eskola O; Lehtiö K; Minn H; Marjamäki P; Bergman J; Haaparanta M; Forsback S; Solin O
    J Nucl Med; 2001 Sep; 42(9):1397-404. PubMed ID: 11535732
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of [18F]fluoroetanidazole, a new radiopharmaceutical for detecting tumor hypoxia.
    Rasey JS; Hofstrand PD; Chin LK; Tewson TJ
    J Nucl Med; 1999 Jun; 40(6):1072-9. PubMed ID: 10452326
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of F-18-labeled fluoroerythronitroimidazole as a PET agent for imaging tumor hypoxia.
    Yang DJ; Wallace S; Cherif A; Li C; Gretzer MB; Kim EE; Podoloff DA
    Radiology; 1995 Mar; 194(3):795-800. PubMed ID: 7862981
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fully automated one-pot synthesis of [18F]fluoromisonidazole.
    Tang G; Wang M; Tang X; Gan M; Luo L
    Nucl Med Biol; 2005 Jul; 32(5):553-8. PubMed ID: 15982586
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Development of [18F]FRP-170 injection for imaging hypoxia by PET].
    Ishikawa Y; Funaki Y; Iwata R; Furumoto S; Nakata E; Kudo Y; Kaneta T; Hakamatsuka T; Takai Y; Yamada S
    Kaku Igaku; 2005 Feb; 42(1):1-10. PubMed ID: 15794116
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Myocardial kinetics of fluorine-18 misonidazole: a marker of hypoxic myocardium.
    Shelton ME; Dence CS; Hwang DR; Welch MJ; Bergmann SR
    J Nucl Med; 1989 Mar; 30(3):351-8. PubMed ID: 2738664
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A radiosynthesis of fluorine-18 fluoromisonidazole.
    Grierson JR; Link JM; Mathis CA; Rasey JS; Krohn KA
    J Nucl Med; 1989 Mar; 30(3):343-50. PubMed ID: 2738663
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative pharmacokinetics, biodistribution, metabolism and hypoxia-dependent uptake of [18F]-EF3 and [18F]-MISO in rodent tumor models.
    Mahy P; De Bast M; de Groot T; Cheguillaume A; Gillart J; Haustermans K; Labar D; Grégoire V
    Radiother Oncol; 2008 Dec; 89(3):353-60. PubMed ID: 18649964
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.